Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-512 in advanced or metastatic solid tumors
NCT07215637Phase 1Recruiting
- Sponsor
- Chong Kun Dang Holdings
- Start
- Oct 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of CKD-512 in solid tumor (advanced stage) and metastatic solid tumor, sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum tolerated dose or Optimal biologically effective dose at 2 years and Recommended dose for expansion at 2 years. Started Oct 2025; status: recruiting.
02
Drugs
CKD-512
03
Conditions
solid tumor (advanced stage)metastatic solid tumor
Beyond the preview
Go deeper on NCT07215637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07215637.